WASHINGTON - FDA's Center for Drug Evaluation and Research (CDER) has embarked on a "transformation initiative" that it will soon ask companies and other stakeholders to join,

CDER Director Janet Woodcock last week told BioCentury that the center's preliminary proposals for change will be posted on the Internet in about a month, and will be discussed with the biomedical community, patients and other interested parties.